TY - JOUR
KW - Abuse-Deterrent Formulations/methods
KW - Administration, Intranasal
KW - Adult
KW - Analgesics, Opioid/administration & dosage/chemistry
KW - Cross-Over Studies
KW - Delayed-Action Preparations/administration & dosage/chemistry
KW - Double-Blind Method
KW - Drug Compounding
KW - Female
KW - Follow-Up Studies
KW - Humans
KW - Male
KW - Morphine/administration & dosage/chemistry
KW - Opioid-Related Disorders/drug therapy/psychology
KW - Young Adult
KW - Abuse Deterrent
KW - opioid abuse
KW - pain
KW - Snorting
AU - L. R. Webster
AU - C. Pantaleon
AU - M. S. Shah
AU - R. DiFalco
AU - M. Iverson
AU - M. D. Smith
AU - E. R. Kinzler
AU - S. Aigner
A1 - 
AD - PRA Health Sciences, Salt Lake City, Utah.; Inspirion Delivery Technologies, LLC, Valley Cottage, New York.; Cerovene, Inc., Valley Cottage, New York, USA.; Cerovene, Inc., Valley Cottage, New York, USA.; Inspirion Delivery Technologies, LLC, Valley Cottage, New York.; PRA Health Sciences, Salt Lake City, Utah.; Inspirion Delivery Technologies, LLC, Valley Cottage, New York.; Inspirion Delivery Technologies, LLC, Valley Cottage, New York.
BT - Pain medicine (Malden, Mass.)
C5 - Opioids & Substance Use
CP - 7
CY - England
DO - 10.1093/pm/pnw213
IS - 7
JF - Pain medicine (Malden, Mass.)
M1 - Journal Article
PB - American Academy of Pain Medicine
PP - England
PY - 2017
SN - 1526-4637; 1526-2375
SP - 1303
EP - 1313
EP - 
T1 - A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Intranasal Drug Liking Study on a Novel Abuse-Deterrent Formulation of Morphine-Morphine ARER
T2 - Pain medicine (Malden, Mass.)
TI - A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Intranasal Drug Liking Study on a Novel Abuse-Deterrent Formulation of Morphine-Morphine ARER
U1 - Opioids & Substance Use
U2 - 27651506
U3 - 10.1093/pm/pnw213
VL - 18
VO - 1526-4637; 1526-2375
Y1 - 2017
Y2 - Jul 1
ER -